Estimated total change in public and private retail spending on prescription drugs with universal public coverage, all provinces combined
| Spending | Actual retail spending 2012/13, $ millions | Change in spending, $ millions (% change) | ||
|---|---|---|---|---|
| Base scenario | All model parameters set to worst-case scenario values* | All model parameters set to best-case scenario values* | ||
| Public | ||||
| Direct public spending on public drug plans | 9 725 | 3 383 (35) | 7 813 (80) | −438 (−5) |
| Indirect public spending on private drug plans | 2 425 | −2 425 (−100) | −2 425 (−100) | −2 425 (−100) |
| Subtotal | 12 151 | 958 (8) | 5 388 (44) | −2 863 (−24) |
| Private | ||||
| Private-sector spending on private drug plans | 5 659 | −5 659 (−100) | −5 659 (−100) | −5 659 (−100) |
| Patient out-of-pocket spending | 4 534 | −2 556 (−56) | −3 911 (−86) | −896 (−20) |
| Subtotal | 10 193 | −8 215 (−81) | −9 569 (−94) | −6 555 (−64) |
| Total | 22 344 | −7 257 (−32) | −4 181 (−19) | −9 418 (−42) |
↵* From the perspective of assessing the cost-impact to government.